Cameras that can scan an entire body in a fraction of a second can give spinal surgeons an accurate assessment of how much range of motion youth with scoliosis have in their torso – a critical piece of information for guiding management of people with the condition, researchers at Hospital for Special Surgery in New […]
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration’s Office of Therapeutic Products has accepted the Company’s Biologics License Application resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.
Insurance lobbyists argue that the 1.03% plan increase is insufficient and, in combination with other changes, would actually result in payment cuts.
Medtronic’s device didn’t outperform competing systems being developed by J&J and Boston Scientific, but the results should be enough to secure FDA approval, one analyst wrote.
Medtronic’s pulsed field ablation device meets safety, efficacy metrics in trial Read More »
The results show that low-risk aortic stenosis patients have better outcomes after three years when catheters are used to insert their replacement heart valves, rather than traditional open-heart surgery.
BridgeBio posted data Monday from its small but highly anticipated Phase II study of infigratinib in achondroplasia – a drug that could give BioMarin a run for its money.
Small Study of BridgeBio’s Dwarfism Drug Indicates Advantage over BioMarin Read More »
FTC Commissioner Christine Wilson said she would have supported an even longer extension since the proposed rule is “a departure from hundreds of years of precedent.”
FTC pushes back deadline for public to weigh in on noncompete ban Read More »
The extra time to certify medical devices in Europe is intended to prevent shortages, but the regulatory overhaul still poses problems for medtech firms, U.S. lobbying group says.
AdvaMed calls EU MDR extension a ‘strong step forward,’ but warns challenges remain Read More »
Volastra Therapeutics has in-licensed Amgen’s sovilnesib, a KIF18A inhibitor being studied for high-grade ovarian cancer, triple-negative breast cancer and other solid tumors.
Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor Read More »
The plan — part of Biden’s 2024 budget proposal set to be released Thursday — would further reduce what Medicare pays for prescription drugs and raise taxes on Americans earning over $400,000.
Biden’s plan to improve Medicare solvency targets prescription drugs Read More »
